EUVIMEDOpdag EUVIMED
Kohortenstudie

Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study

Liying Du, Liman Huo, Juan Hou, Xiajin Zhou, Mingfeng Liu, Teng Guo, Wei Wang, Huihui Chen, Xinran Chen iD

Biopharmaceutics & Drug Disposition · 2023-04 · 44 (2) · 175-182

DOI: 10.1002/bdd.2354 ↗

At a glance

Kohortenstudie in Biopharmaceutics & Drug Disposition, published online on 2023-03-28. Written by Liying Du and 8 co-authors. Institution: Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. Major MEDLINE topics: Anti-Bacterial Agents, Kidney Failure, Chronic. Cited 1 times so far (Crossref); 14 references. Funded by: The key project plan for health and medical science research in Hebei Provincial Health Commission.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Blood concentration monitoring plays an important role in the rational use of norvancomycin. However, the reference interval for the norvancomycin plasma concentration in the treatment of infections in hemodialysis patients with end stage kidney disease is undefined. To determine the safe and effective interval for the norvancomycin plasma trough concentration, 39 patients treated with hemodialysis and norvancomycin were analyzed retrospectively. The norvancomycin plasma concentration before hemodialysis was tested as the trough concentration. The associations of the norvancomycin trough concentration with efficacy and adverse reactions were evaluated. No norvancomycin concentration above 20 μg/mL was detected. The trough concentration, but not the dose, had a significant effect on the anti‐infectious efficacy. Compared with the low norvancomycin trough concentration group (

Subjects

MeSH terms (MEDLINE)

Anti-Bacterial AgentsKidney Failure, ChronicHumansRetrospective StudiesRenal Dialysis

Author keywords

blood concentration monitoringend stage kidney diseasehemodialysisinfectionnorvancomycin

Substances

Anti-Bacterial Agents

Authors and institutions

  • Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Department of Clinical Laboratory, Hebei General Hospital, Shijiazhuang, China.
  • Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

ORCID profiles: Xinran Chen

Funding

  • The key project plan for health and medical science research in Hebei Provincial Health Commission

Cite

APA

Du, L., Huo, L., Hou, J., Zhou, X., Liu, M., Guo, T., Wang, W., Chen, H., & Chen, X. (2023). Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study. Biopharmaceutics & Drug Disposition, 44(2), 175-182. https://doi.org/10.1002/bdd.2354

Vancouver

Du L, Huo L, Hou J, Zhou X, Liu M, Guo T, et al. Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study. Biopharmaceutics & Drug Disposition. 2023;44(2):175-182. doi:10.1002/bdd.2354

BibTeX
@article{Du2023,
  author = {Du, Liying and Huo, Liman and Hou, Juan and Zhou, Xiajin and Liu, Mingfeng and Guo, Teng and Wang, Wei and Chen, Huihui and Chen, Xinran},
  title = {Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study},
  journal = {Biopharmaceutics & Drug Disposition},
  year = {2023},
  volume = {44},
  number = {2},
  pages = {175--182},
  doi = {10.1002/bdd.2354}
}
Start for free →